Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 312

1.

Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.

Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Kline Z, Belt P, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Anticancer Res. 2019 Sep;39(9):4781-4786. doi: 10.21873/anticanres.13662.

PMID:
31519579
2.

Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Kiyuna T, Tome Y, Miyake K, Murakami T, Oshiro H, Igarashi K, Kawaguchi K, Hsu J, Singh M, Li Y, Nelson S, Bouvet M, Singh SR, Kanaya F, Hoffman RM.

Anticancer Res. 2019 Sep;39(9):4775-4779. doi: 10.21873/anticanres.13661.

PMID:
31519578
3.

Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.

Oshiro H, Tome Y, Kiyuna T, Yoon SN, Lwin TM, Han Q, Tan Y, Miyake K, Higuchi T, Sugisawa N, Katsuya Y, Park JH, Zang Z, Razmjooei S, Bouvet M, Clary B, Singh SR, Kanaya F, Nishida K, Hoffman RM.

Anticancer Res. 2019 Sep;39(9):4667-4671. doi: 10.21873/anticanres.13648.

PMID:
31519565
4.

Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.

Higuchi T, Oshiro H, Miyake K, Sugisawa N, Han Q, Tan Y, Park J, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Chawla SP, Singh SR, Tsuchiya H, Hoffman RM.

Anticancer Res. 2019 Sep;39(9):4653-4657. doi: 10.21873/anticanres.13646.

PMID:
31519563
5.

Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes.

Chakladar J, Li WT, Bouvet M, Chang EY, Wang-Rodriguez J, Ongkeko WM.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1179. doi: 10.3390/cancers11081179.

6.

Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.

Park JH, Zhao M, Han Q, Sun Y, Higuchi T, Sugisawa N, Yamamoto J, Singh SR, Clary B, Bouvet M, Hoffman RM.

Biochem Biophys Res Commun. 2019 Oct 15;518(2):306-310. doi: 10.1016/j.bbrc.2019.08.051. Epub 2019 Aug 14.

PMID:
31421825
7.

Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.

Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Anticancer Res. 2019 Aug;39(8):4079-4084. doi: 10.21873/anticanres.13565.

PMID:
31366491
8.

Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis.

Yoon SN, Park JH, Lwin TM, Miyake K, Singh SR, Hoffman RM, Bouvet M.

Anticancer Res. 2019 Aug;39(8):4065-4071. doi: 10.21873/anticanres.13563.

PMID:
31366489
9.

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.

Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Transl Oncol. 2019 Sep;12(9):1257-1263. doi: 10.1016/j.tranon.2019.06.002. Epub 2019 Jul 9.

10.

Peritoneal Metastases in a Patient-derived Orthotopic Xenograft (PDOX) Model of Colon Cancer Imaged Non-invasively via Red Fluorescent Protein Labeled Stromal Cells.

Park JH, Zhao M, Oshiro H, Miyake K, Higuchi T, Reynoso J, Razmjooei S, Bouvet M, Clary B, Zhang Z, Sugisawa N, Yamamoto J, Singh SR, Hoffman RM.

Anticancer Res. 2019 Jul;39(7):3463-3467. doi: 10.21873/anticanres.13492.

PMID:
31262870
11.

Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumors.

Yazaki P, Lwin T, Minnix M, Li L, Sherman A, Molnar J, Miller A, Frankel P, Chea J, Poku E, Bowles N, Hoffman R, Shively J, Bouvet M.

J Biomed Opt. 2019 Jun;24(6):1-9. doi: 10.1117/1.JBO.24.6.066012.

12.

Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses.

Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, Minev B, Ma W.

Drug Deliv Transl Res. 2019 Jun 21. doi: 10.1007/s13346-019-00652-z. [Epub ahead of print]

PMID:
31228097
13.

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.

Miyake K, Higuchi T, Oshiro H, Zhang Z, Sugisawa N, Park JH, Razmjooei S, Katsuya Y, Barangi M, Li Y, Nelson SD, Murakami T, Homma Y, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM.

Biomed Pharmacother. 2019 Sep;117:109093. doi: 10.1016/j.biopha.2019.109093. Epub 2019 Jun 11.

14.

RE: "Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin Assessment During Pancreatic Resection".

Bouvet M, Lwin TM, Hoffman RM.

Ann Surg. 2019 Jul;270(1):21-22. doi: 10.1097/SLA.0000000000003360. No abstract available.

PMID:
31188174
15.

Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.

Oshiro H, Tome Y, Kiyuna T, Miyake K, Kawaguchi K, Higuchi T, Miyake M, Zang Z, Razmjooei S, Barangi M, Wangsiricharoen S, Nelson SD, Li Y, Bouvet M, Singh SR, Kanaya F, Hoffman RM.

Tissue Cell. 2019 Jun;58:17-23. doi: 10.1016/j.tice.2019.04.002. Epub 2019 Apr 3.

PMID:
31133242
16.

Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models.

Hollandsworth HM, Lwin TM, Amirfakhri S, Filemoni F, Batra SK, Hoffman RM, Dhawan P, Bouvet M.

J Surg Res. 2019 Oct;242:145-150. doi: 10.1016/j.jss.2019.04.048. Epub 2019 May 9.

PMID:
31077946
17.

Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.

Higuchi T, Miyake K, Oshiro H, Sugisawa N, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Biochem Biophys Res Commun. 2019 May 28;513(2):326-331. doi: 10.1016/j.bbrc.2019.03.191. Epub 2019 Apr 5.

PMID:
30955860
18.

Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model.

Miyake K, Murata T, Murakami T, Zhao M, Kiyuna T, Kawaguchi K, Igarashi K, Miyake M, Lwin TM, Hozumi C, Komatsu S, Kikuchi T, Bouvet M, Shimoya K, Singh SR, Endo I, Hoffman RM.

Arch Gynecol Obstet. 2019 Jun;299(6):1683-1690. doi: 10.1007/s00404-019-05147-3. Epub 2019 Apr 5.

PMID:
30953192
19.

The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.

Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1075-1082. doi: 10.1007/s00280-019-03824-3. Epub 2019 Mar 30.

PMID:
30929053
20.

Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.

Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Cancer Lett. 2019 Jun 1;451:122-127. doi: 10.1016/j.canlet.2019.03.003. Epub 2019 Mar 10.

PMID:
30867142

Supplemental Content

Loading ...
Support Center